Tag:

atrial fibrillation

Latest Headlines

Latest Headlines

Advanced Cardiac Therapeutics raises $7M-plus for ablation catheter technology

Advanced Cardiac Therapeutics closed a new round of equity financing to support development of its innovative ablation catheter for atrial fibrillation.

Medtronic gives it another go with atrial fibrillation device

Medtronic is looking make its device the first to be FDA-approved for long-running atrial fibrillation, shaking off a 2011 setback and kicking-starting enrollment in a new pivotal trial.

Topera snags FDA OK for latest heart-mapping tech

Topera Medical picked up FDA clearance for the latest generation of its 3-D Mapping System, a device designed to help diagnose cardiac arrhythmias without invasive surgery.

AtriCure grabs ablation device maker Estech for $34M

AtriCure is set to acquire California-based surgical ablation device maker Estech in a deal worth at least $34 million and almost double that amount down the line.

Daiichi's a-fib drug aces PhIII, faces crowded market

Daiichi Sankyo's atrial fibrillation-treating edoxaban posted promising results in Phase III, matching the stroke-prevention prowess of warfarin with a better safety profile, but the drug may struggle to carve out market share in a cluttered space.

Boston Scientific sets FDA date for closely watched Watchman

Boston Scientific is ticking closer to judgment day for its much-scrutinized Watchman device, securing an FDA advisory hearing for a stroke-fighting implant that has faced doubts throughout its development.

U.K. crew eyes biomarker as flag for atrial fibrillation complications

Patients with atrial fibrillation, a common cardiac arrhythmia, are often at a heightened risk for stroke and other health problems. But researchers in the U.K. and elsewhere believe they have identified a biomarker that can help screen for folks who face a greater likelihood of complications.

Medtronic's tech halves atrial fibrillation risk

Heart failure patients treated with a Medtronic defibrillator were roughly half as likely to endure atrial fibrillation than were those using other devices, according to a study.

Gore beats back St. Jude's patent suit

After a three-year legal spat, Gore has prevailed over St. Jude Medical and can keep its heart plug on the market, the company said.

Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII

Isis Pharmaceuticals has opted to throw in the towel on its rheumatoid arthritis program for ISIS-CRP Rx, but the biotech says it will continue to plug away at studies of the antisense treatment for other diseases, including a mid-stage trial for atrial fibrillation due to read out next year.